President-elect Donald Trump wants to buy the territory from Denmark, which says it’s not for sale. DealBook asked experts ...

President-elect Donald Trump 's threat to "tariff Denmark at a very high level" if it refuses to give up Greenland could ...

Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a fair price target of $1,200. See more.

Deutsche Bank analyst Emmanuel Papadakis lowered the firm’s price target on Novo Nordisk (NVO) to DKK 900 from DKK 1,000 and keeps a Buy rating ...

Goldman Sachs analyst James Quigley maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK875.00.

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

These companies have track records of success, increasing dividends, and fantastic growth prospects, making them all ideal ...

A new request by Ozempic manufacturer Novo Nordisk could limit the availability of a type of GLP-1—semaglutides—to local ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

This week, the FDA granted priority review status to J&J’s JNJ application seeking approval of key pipeline candidate ...

Key Takeaways Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for ...

Here are 11 healthcare industry lawsuits, settlements and legal developments that Becker's has reported since Jan. 3: ...